Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Park, Silvia ^a   Lee, Jeeyun ^a   Do, In Gu ^a   Jang, Jiryeon ^a   Rho, Kyoohyoung ^b   Ahn, Seonjoo ^b   Maruja, Lira ^c   Kim, Sung Joo ^a   Kim, Kyoung Mee ^a   Mao, Mao ^c   Oh, Ensel ^d   Kim, Yu Jin ^d   Kim, Jhingook ^a   Choi, Yoon La ^a  

^a Sungkyunkwan University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c PFIZER INC   (United States)

^d Samsung Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CDK4 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 4;

ADULT; ARTICLE; CASE REPORT; CHROMOSOME 12; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; HUMAN GENOME; MALE; METASTASIS; PATHOLOGY; RADIOGRAPHY; RHABDOMYOSARCOMA;

ADULT; CHROMOSOMES, HUMAN, PAIR 12; COMPARATIVE GENOMIC HYBRIDIZATION; CYCLIN-DEPENDENT KINASE 4; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; MALE; NEOPLASM METASTASIS; RHABDOMYOSARCOMA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84892168232     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03623     Document Type: Article

References (36)

1. Ognjanovic, S., Linabery, A. M., Charbonneau, B. & Ross, J. A. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer 115, 4218-4226 (2009).
2. Ferrari, A. et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer 98, 571-580 (2003). (Pubitemid 36885998)
3. Esnaola, N. F. et al. Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Ann. Surg. 234, 215-223 (2001). (Pubitemid 32729429)
4. Hawkins, W. G. et al. Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer 91, 794-803 (2001). (Pubitemid 32173305)
5. Meza, J. L., Anderson, J., Pappo, A. S. & Meyer, W. H. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J. Clin. Oncol. 24, 3844-3851 (2006). (Pubitemid 46630730)
6. McDowell, H. P. et al. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98. Eur. J. Cancer 46, 1588-1595 (2010).
7. Carli, M. et al. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J. Clin. Oncol. 22, 4787-4794 (2004).
8. Breneman, J. C. et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-a report from the Intergroup Rhabdomyosarcoma Study IV. J. Clin. Oncol. 21, 78-84 (2003).
9. Pappo, A. S. et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. J. Clin. Oncol. 17, 3487-3493 (1999). (Pubitemid 29517919)
10. Little, D. J. et al. Adult rhabdomyosarcoma: outcome following multimodality treatment. Cancer 95, 377-388 (2002). (Pubitemid 34787604)
11. Parham, D. M. & Ellison, D. A. Rhabdomyosarcomas in adults and children: an update. Arch. Pathol. Lab. Med. 130, 1454-1465 (2006). (Pubitemid 44520712)
12. Sorensen, P. H. et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J. Clin. Oncol. 20, 2672-2679 (2002). (Pubitemid 34575640)
13. Davicioni, E. et al.Molecular classification of rhabdomyosarcoma- genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am. J. Pathol. 174, 550-564 (2009).
14. Davicioni, E. et al. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res. 66, 6936-6946 (2006). (Pubitemid 44197668)
15. Reichek, J. L. et al. Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Clin. Cancer Res. 17, 1463-1473 (2011).
16. Missiaglia, E. et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J. Clin. Oncol. 30, 1670-1677 (2012).
17. van Gaal, J. C. et al. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. J. Clin. Oncol. 30, 308-315 (2012).
18. Corao, D. A. et al. ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status. Pediatr. Dev. Pathol. 12, 275-283 (2009).
19. Pillay, K., Govender, D. & Chetty, R. ALK protein expression in rhabdomyosarcomas. Histopathology 41, 461-467 (2002). (Pubitemid 35335007)
20. Mazzoleni, S. et al. Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Cancer 104, 183-190 (2005). (Pubitemid 40847767)
21. Turajlic, S. et al. Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res. 22, 196-207 (2012).
22. Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005 (2010).
23. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010).
24. Momand, J., Zambetti, G. P., Olson, D. C., George, D. & Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245 (1992).
25. Singer, S. et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res. 67, 6626-6636 (2007). (Pubitemid 47105508)
26. Louis-Brennetot, C. et al. The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumors. Genes Chromosomes Cancer 50, 896-907 (2011).
27. Wolf, M. et al. Microsatellite markers as tools for characterization of DNA amplifications evaluated by comparative genomic hybridization. Cancer Genet. Cytogenet. 93, 33-38 (1997). (Pubitemid 27102487)
28. Szymanska, J. et al. Gains and losses of DNA sequences in liposarcomas evaluated by comparative genomic hybridization. Genes Chromosomes Cancer 15, 89-94 (1996). (Pubitemid 26048408)
29. Dickson, M. A. et al. Phase II trial of the CDK4 inhibitor PD0332991 in CDK4-amplified liposarcoma. J. Clin. Oncol. 30 (Suppl), Abstr 10002 (2012).
30. Forus, A. et al. Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2. Cell Growth Differ. 4, 1065-1070 (1993). (Pubitemid 2020828)
31. Anderson, J., Gordon, A., Pritchard-Jones, K. & Shipley, J. Genes, chromosomes, and rhabdomyosarcoma. Genes Chromosomes Cancer 26, 275-285 (1999).
32. Missiaglia, E. et al. Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. Genes Chromosomes Cancer 48, 455-467 (2009).
33. Barr, F. G. et al. Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Genes Chromosomes Cancer 48, 661-672 (2009).
34. Saab, R. et al. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Mol. Cancer Ther. 5, 1299-1308 (2006). (Pubitemid 43881323)
35. Cao, L. et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res. 70, 6497-6508 (2010).
36. Lira, M. E. et al. Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer. J. Mol. Diagn. 15, 51-61 (2013).